
    
      This is a study involving a 2-4 week run-in phase followed by a 12 week double blind
      treatment phase. During the run-in phase, all subjects receive Flixotide. In the treatment
      phase subjects will be randomised to one of the 3 treatment groups and will receive active
      Flutiform and placebo Flixotide or Active Seretide and placebo Flixotide or active Flixotide
      and either placebo seretide or placebo Flutiform. Efficacy will be assessed by lung function
      tests, asthma symptoms, sleep disturbance due to asthma and rescue medication use. Safety
      will be assessed by adverse events, lab tests, urinary cortisol and vital signs.
    
  